Welcome to our dedicated page for Omeros news (Ticker: OMER), a resource for investors and traders seeking the latest updates and insights on Omeros stock.
Omeros Corporation develops and commercializes protein and small-molecule therapeutics for large-market and orphan indications, with emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its news centers on YARTEMLEA (narsoplimab-wuug), an FDA-approved MASP-2 lectin pathway inhibitor for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adult and pediatric patients aged two years and older.
Recurring updates also cover U.S. commercialization, reimbursement coding, transplant-medicine presentations, operating and financial results, and pipeline work including OMS1029, a long-acting MASP-2 inhibitor, and OncotoX-AML, an oncology therapeutic platform targeting acute myeloid leukemia.
Omeros Corporation (Nasdaq: OMER) presented its OMS906 program data at the 4th Complement-based Drug Development Summit. OMS906 targets MASP-3, a key activator in the complement system's alternative pathway, aiming to inhibit its activation. The animal study data revealed that a single dose reduced mature complement factor D levels while increasing pro-complement factor D levels. Omeros targets paroxysmal nocturnal hemoglobinuria (PNH) as the first indication, with OMS906 showing greater potency than current C5 and C3 inhibitors. A Phase 1 clinical trial for OMS906 began last month.
Omeros Corporation (Nasdaq: OMER) will present final results from its pivotal trial of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a webcast on October 22, 2020, at 8:30 a.m. ET. The data will support their Biologics Licensing Application (BLA) to the FDA, detailing primary and secondary efficacy endpoints including complete response rate and overall survival. The trial also incorporates data from a compassionate-use program, affirming the safety profile. Interested parties can access the webcast or dial in via phone for participation.